Aggressive ductal adenocarcinoma with painless jaundice (head) or vague back pain (body/tail); poor prognosis.
Also known as: pancreatic cancer, pancreatic adenocarcinoma, PDAC
Overview
Malignant neoplasm of the pancreas; >85% are ductal adenocarcinomas (PDAC). Less common: cystic neoplasms (IPMN, MCN), neuroendocrine tumors, acinar cell carcinoma.
Epidemiology
~64,000 new cases and ~51,000 deaths annually in the US — 3rd leading cancer killer; projected to be 2nd by 2030. 5-year survival ~12% (recently improving). Most diagnosed at advanced stage. Median age at diagnosis 70.
Try two board-style Pancreatic Adenocarcinoma questions
Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.
Question 1GastrointestinalEasy
A 65-year-old man has 2 months of progressive painless jaundice and a 15-lb weight loss. CT of the abdomen shows simultaneous dilation of the common bile duct and the pancreatic duct (double duct sign) with a mass at the pancreatic head. CA 19-9 is 850 U/mL. Which of the following is the most likely diagnosis?
ACholangiocarcinoma
BPancreatic adenocarcinoma
CCholedocholithiasis
DAutoimmune pancreatitis
EGallbladder carcinoma
Reveal answer & full explanation
Correct answer: B — Pancreatic adenocarcinoma
ACholangiocarcinoma
BPancreatic adenocarcinoma✓
CCholedocholithiasis
DAutoimmune pancreatitis
EGallbladder carcinoma
Why Pancreatic adenocarcinoma is correct
The double duct sign, simultaneous dilation of the common bile duct and the pancreatic duct, classically results from a mass at the pancreatic head obstructing both ducts
Progressive painless jaundice with significant weight loss is the textbook presentation of pancreatic head adenocarcinoma
A markedly elevated CA 19-9 (850 U/mL) supports the diagnosis and is used to follow treatment response
Resectable disease (no vascular invasion or metastases) is managed with pancreaticoduodenectomy (Whipple procedure)
Why the others are wrong
Autoimmune pancreatitis — can mimic malignancy with obstructive jaundice, but typically shows a sausage-shaped gland, elevated IgG4, and a response to steroids; a discrete pancreatic-head mass with high CA 19-9 and weight loss points to cancer (confused-with-malignancy mimic)
Cholangiocarcinoma — also causes painless jaundice and elevated CA 19-9, but the double duct sign with a pancreatic-head mass localizes the lesion to the pancreas rather than the bile duct (buzzword-matching on painless jaundice)
Choledocholithiasis — usually causes painful, fluctuating jaundice without weight loss and would show a ductal stone rather than a pancreatic-head mass (premature closure on a common biliary cause)
Gallbladder carcinoma — can also cause jaundice, weight loss, and an elevated CA 19-9, but it arises in the gallbladder, often presents with right upper quadrant pain, and typically causes jaundice by invading the common hepatic duct or hilum; a mass at the pancreatic head with dilation of both the common bile duct and the pancreatic duct localizes the tumor to the pancreas instead (lumping pancreaticobiliary cancers together)
Question 2GastrointestinalMedium
A 52-year-old man has 4 weeks of painless jaundice, a palpable non-tender gallbladder, a 15-lb weight loss, and new-onset diabetes. CA 19-9 is 1,200 U/mL. CT shows a 3.5-cm pancreatic head mass with solid tumor contact involving more than 180° of the superior mesenteric vein circumference, but with a patent vein segment suitable for reconstruction above and below the tumor. There is no arterial contact and no distant metastasis. Which of the following best characterizes this tumor's resectability?
ALocally advanced unresectable
BUnresectable based on tumor size
CResectable
DUnresectable based on CA 19-9
EBorderline resectable
Reveal answer & full explanation
Correct answer: E — Borderline resectable
ALocally advanced unresectable
BUnresectable based on tumor size
CResectable
DUnresectable based on CA 19-9
EBorderline resectable✓
Why Borderline resectable is correct
Per current NCCN criteria, a pancreatic head tumor with solid contact of the superior mesenteric vein or portal vein greater than 180°, but with a vein segment still suitable for reconstruction and no arterial involvement, is borderline resectable
Borderline-resectable disease is treated with neoadjuvant chemotherapy (e.g., FOLFIRINOX) followed by restaging and pancreaticoduodenectomy (Whipple) if the tumor remains resectable
Painless jaundice with a palpable non-tender gallbladder (Courvoisier sign), weight loss, new-onset diabetes, and a markedly elevated CA 19-9 are classic features of pancreatic head adenocarcinoma
Why the others are wrong
Resectable — Resectable disease requires no arterial contact AND venous contact of 180° or less without contour irregularity; the greater-than-180° venous involvement here exceeds that threshold (the trap of overlooking the degree of venous contact)
Locally advanced unresectable — This requires more than 180° of arterial encasement or venous involvement that cannot be reconstructed; this tumor has no arterial contact and a reconstructable vein (anchoring on any vascular contact as automatically unresectable)
Unresectable based on tumor size — Tumor diameter is not a resectability criterion; NCCN defines resectability by arterial and venous contact, so a 3.5-cm head mass with no arterial contact and a reconstructable vein remains borderline (confusing tumor bulk with vascular anatomy)
Unresectable based on CA 19-9 — a CA 19-9 of 1,200 U/mL is alarming and raises concern for occult metastatic disease, but anatomic resectability is defined by arterial and venous contact on imaging; a markedly elevated marker at most flags high-risk biology that favors neoadjuvant therapy and staging laparoscopy, and it is also raised by biliary obstruction in a jaundiced patient, so a high CA 19-9 alone does not make a tumor unresectable (confusing tumor biology with vascular anatomy)
That's 2. Get 7,700+ more.
Unlock the full FirstPassPA bank: 7,700+ board-style questions, flashcards, and an AI tutor that explains every answer. Your 7-day free trial includes everything, and there's no credit card required.
You've read your 2 free diagnosis previews. Create your free account to unlock the full Pancreatic Adenocarcinoma outline — plus all 514 diagnoses, 7,700+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
IPMN / mucinous cystic neoplasm — Cystic lesion; high-risk stigmata (obstructive jaundice with a head cyst, enhancing mural nodule ≥5 mm, main duct ≥10 mm) warrant resection; worrisome features (cyst ≥3 cm, main duct 5-9 mm, thickened walls) warrant EUS
Pancreatic pseudocyst — History of pancreatitis; absence of mural nodule or septations on EUS
Ampullary or duodenal carcinoma — Periampullary mass on EUS/ERCP
Diagnostic workup
Diagnostic criteria
Histologic confirmation by EUS-FNA preferred for non-resectable disease (allows molecular profiling). Resectable tumors may proceed to surgery based on imaging without pre-op biopsy if imaging is characteristic, but tissue confirmation (EUS-FNA preferred) is required before any neoadjuvant therapy. AJCC TNM staging. Resectability classification: resectable, borderline resectable (vascular abutment), locally advanced (encasement of major vessels), metastatic.
Labs
LFTs — direct hyperbilirubinemia, elevated alk phos in obstructive (head) tumors
CBC, BMP, albumin (nutritional status)
Lipase usually normal (unlike acute pancreatitis)
CA 19-9 — elevated in ~80%; useful for monitoring response and recurrence; false positives in cholestasis/cholangitis, pancreatitis, and cirrhosis; false NEGATIVES in Lewis antigen-negative individuals (~5-10% of people cannot make CA 19-9)
CEA — less specific
Glucose, HbA1c (new diabetes association)
Coagulation (vitamin K deficiency in cholestasis)
Imaging
Multiphase pancreas-protocol CT (arterial and venous phases) — modality of choice for diagnosis, staging, and resectability assessment
MRI/MRCP — better characterization of pancreatic cystic lesions and indeterminate liver lesions
EUS — most sensitive for small lesions and lymph node assessment; tissue diagnosis via FNA
ERCP — therapeutic (stenting for biliary decompression); double-duct sign (dilated CBD and pancreatic duct) — classic for head tumor
PET-CT — selected cases for distant metastases
Diagnostic laparoscopy with peritoneal washings — recommended for body/tail tumors and high-risk head tumors before resection (occult peritoneal disease in 15-25%)
Diagnostic algorithm
Resectability Class
Imaging Criteria
Initial Management
Resectable
No arterial contact; ≤180° contact with SMV/PV without contour irregularity
Upfront surgery + adjuvant mFOLFIRINOX; consider neoadjuvant chemo (after EUS-FNA biopsy) for high-risk features
Borderline resectable
Limited arterial contact (CHA, SMA <180°); SMV/PV reconstructable
Neoadjuvant chemo ± chemoradiation, then restage
Locally advanced (unresectable)
Encasement of SMA/celiac >180°; unreconstructable SMV/PV
Multidisciplinary team management at high-volume center
Stage- and resectability-directed therapy (see by_subtype)
Pain control, nutritional support, biliary stenting for obstruction
Pancreatic enzyme replacement for exocrine insufficiency
Resectable
Standard: upfront resection followed by adjuvant chemotherapy; neoadjuvant chemotherapy (FOLFIRINOX or gemcitabine + nab-paclitaxel) may be considered for high-risk features (very high CA 19-9, large primary tumor or regional nodes, excessive weight loss, severe pain) and requires tissue confirmation (EUS-FNA) first
Pancreaticoduodenectomy (Whipple) for head tumors
Distal pancreatectomy ± splenectomy for body/tail tumors
Neoadjuvant chemotherapy (FOLFIRINOX or gem-nab) ± chemoradiation
Restage; surgery if downstaged to resectable
Locally advanced (unresectable)
Systemic chemotherapy: FOLFIRINOX or gem-nab-paclitaxel
Consider chemoradiation after induction chemotherapy in selected patients
Palliative biliary and duodenal stenting for obstruction
Celiac plexus neurolysis for pain
Metastatic
First-line: FOLFIRINOX or NALIRIFOX (good performance status) or gemcitabine + nab-paclitaxel
BRCA1/2 or PALB2 mutation: platinum-based regimen; germline BRCA1/2 with disease control after at least 16 weeks of first-line platinum: consider olaparib maintenance (POLO trial)
MSI-H/dMMR (rare in PDAC): pembrolizumab
NTRK or NRG1 fusion: targeted therapy in specialized centers
Second-line: nanoliposomal irinotecan + 5-FU; gemcitabine-based if not previously used
Best supportive and palliative care from diagnosis
Complications
Biliary obstruction with jaundice and pruritus
Gastric outlet obstruction (duodenal invasion)
Pancreatic duct obstruction with exocrine insufficiency
Cachexia and malnutrition
Migratory thrombophlebitis (Trousseau)
Venous thromboembolism (high risk)
Pain — refractory, requires multimodal management including celiac plexus block
Diabetes (type 3c) — brittle
Depression
Metastases — liver (most common), peritoneum, lung, bone
Painless obstructive jaundice + palpable nontender gallbladder (Courvoisier sign) in older adult = pancreatic head cancer until proven otherwise.
Double-duct sign (dilated CBD and pancreatic duct) on cross-sectional imaging strongly suggests pancreatic head tumor.
CA 19-9 is useful for surveillance and treatment response but NOT for diagnosis (false positives in cholestasis, false negatives in Lewis-negative individuals).
New-onset diabetes after age 50, especially with weight loss, can be paraneoplastic — consider pancreatic imaging.
Tissue diagnosis: EUS-FNA preferred for indeterminate or unresectable lesions; CT-guided biopsy if EUS unavailable; resectable lesions with characteristic imaging may proceed to surgery without preop biopsy.
Whipple (pancreaticoduodenectomy) at high-volume centers reduces morbidity and mortality.
FOLFIRINOX or gemcitabine + nab-paclitaxel are standard first-line systemic regimens.
PRODIGE 24/CCTG PA.6: modified FOLFIRINOX adjuvant therapy significantly improves DFS and OS over gemcitabine in resected pancreatic cancer.
BRCA1/2 mutations occur in 5-9% of PDAC — universal germline testing recommended; opens platinum and PARP inhibitor options.
Universal germline genetic testing now recommended for ALL patients with PDAC (NCCN, ASCO).
Hereditary pancreatic cancer surveillance (AGA 2020): annual MRI/MRCP and/or EUS starting at age 50 (or 10 yr before the youngest affected relative) for familial pancreatic cancer kindreds and for BRCA1/2, PALB2, ATM, or Lynch carriers who have an affected first-degree relative; start at 40 for CDKN2A (FAMMM) and PRSS1 hereditary pancreatitis carriers and at 35 for Peutz-Jeghers.
References
NCCN 2024 — NCCN Guidelines Version 2.2024 — Pancreatic Adenocarcinoma
PRODIGE 24 — Conroy T et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. NEJM 2018;379:2395-2406
POLO Trial — Golan T et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. NEJM 2019;381:317-327
AGA 2020 — Aslanian HR et al. AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals. Gastroenterology 2020;159:358-362
NAPOLI 3 — Wainberg ZA et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet 2023;402:1272-1281
Practice Gastrointestinal questions on FirstPassPA
Turn this outline into retention. 7,700+ board-style questions with an AI tutor that explains every answer — free to start, no card required.
Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.